{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:26:58Z","timestamp":1740126418338,"version":"3.37.3"},"reference-count":20,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Randomized trials comparing chemomobilization efficiency between lenograstim and biosimilar filgrastim are lacking. Our previous retrospective study suggested that lenograstim could be more effective than biosimilar filgrastim when used at the same conventional dosage (5 \u00b5g\/kg) only in lymphoma patients undergoing peripheral blood stem cell mobilization. We planned a prospective randomized study comparing lenograstim 5 \u00b5g\/kg with biosimilar filgrastim 10 \u00b5g\/kg to verify the hypothesis of lenograstim superiority even at half the dosage (stress test). Herein we report data after enrolling 60% of planned patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>From October 2014 to November 2017, a total of 42 of 70 planned patients with lymphoma were randomly assigned to receive lenograstim 5 \u00b5g\/kg (21) or biosimilar filgrastim 10 \u00b5g\/kg (21). Patients were stratified according to treatment line at the time of mobilization (1 or \u22652). Primary endpoint was the rate of achievement of the CD34+ cell collection target dose (\u2265 4\u00a0\u00d7\u00a010<jats:sup>6<\/jats:sup>\/kg). An improvement by 23% was expected to validate the hypothesis of lenograstim superiority.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The two cohorts were balanced for all the baseline features. We observed an identical rate of patients able to reach the targeted CD34+ cell dose and of mobilization failures (90.4 and 4.8% in both cohorts) and a perfect equivalence in any of the secondary collection outcomes. The hypothesis of lenograstim superiority was not corroborated at interim analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Lenograstim at conventional dosage has failed to demonstrate its superiority over biosimilar filgrastim at double the dosage at interim analysis in their first head\u2010to\u2010head trial.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14533","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T11:08:56Z","timestamp":1518692936000},"page":"1143-1148","source":"Crossref","is-referenced-by-count":3,"title":["Lenograstim 5 \u00b5g\/kg is not superior to biosimilar filgrastim 10 \u00b5g\/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study"],"prefix":"10.1111","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7520-7511","authenticated-orcid":false,"given":"Francesco","family":"Marchesi","sequence":"first","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Vacca","sequence":"additional","affiliation":[{"name":"Immuno\u2010Transfusional Medicine, Leukapheresis and Cellular Therapy Unit S. Camillo\u2010Forlanini Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute Regina Elena National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ipsevich","sequence":"additional","affiliation":[{"name":"Immuno\u2010Transfusional Medicine, Leukapheresis and Cellular Therapy Unit S. Camillo\u2010Forlanini Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annino","family":"Pandolfi","sequence":"additional","affiliation":[{"name":"Immuno\u2010Transfusional Medicine, Leukapheresis and Cellular Therapy Unit S. Camillo\u2010Forlanini Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svitlana","family":"Gumenyuk","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Renzi","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Palombi","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pisani","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atelda","family":"Romano","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Spadea","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Papa","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Canfora","sequence":"additional","affiliation":[{"name":"Biostatistics Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute Regina Elena National Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pierelli","sequence":"additional","affiliation":[{"name":"Immuno\u2010Transfusional Medicine, Leukapheresis and Cellular Therapy Unit S. Camillo\u2010Forlanini Hospital Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mengarelli","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Unit"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.05.003"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.39"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03385.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705465"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21206"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-014-0282-9"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.7752"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666160517115907"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.11.008"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24817"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2013.04.007"},{"key":"e_1_2_7_13_1","first-page":"1","article-title":"Biosimilar filgrastim (Zarzio\u00ae) vs Lenograstim (Myelostim\u00ae) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience","volume":"18","author":"Marchesi F","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.11.016"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14211"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.82"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02723.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.04.011"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.05.027"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2003.12.002"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20604"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14533","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:54:24Z","timestamp":1695563664000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/trf.14533"],"URL":"https:\/\/doi.org\/10.1111\/trf.14533","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"type":"print","value":"0041-1132"},{"type":"electronic","value":"1537-2995"}],"subject":[],"published":{"date-parts":[[2018,2,15]]}}}